Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Flavonoids as Therapeutic Agents in Alzheimer’s and Parkinson’s Diseases: A Systematic Review of Preclinical Evidences

2018; Hindawi Publishing Corporation; Volume: 2018; Issue: 1 Linguagem: Inglês

10.1155/2018/7043213

1942-0900

Roxana Braga de Andrade Teles, Tâmara Coimbra Diniz, Tiago Coimbra Costa Pinto, Raimundo Gonçalves de Oliveira Júnior, Mariana Gama e Silva, Érica Martins de Lavor, Antônio Wilton Cavalcante Fernandes, Ana Paula de Oliveira, Fernanda Pires Rodrigues de Almeida Ribeiro, Amanda Alves Marcelino da Silva, Taisy Cinthia Ferro Cavalcante, Lucindo José Quintans‐Júnior, Jackson Roberto Guedes da Silva Almeida,

Alzheimer's disease research and treatments

Alzheimer’s and Parkinson’s diseases are considered the most common neurodegenerative disorders, representing a major focus of neuroscience research to understanding the cellular alterations and pathophysiological mechanisms involved. Several natural products, including flavonoids, are considered able to cross the blood‐brain barrier and are known for their central nervous system‐related activity. Therefore, studies are being conducted with these chemical constituents to analyze their activities in slowing down the progression of neurodegenerative diseases. The present systematic review summarizes the pharmacological effects of flavonoids in animal models for Alzheimer’s and Parkinson’s diseases. A PRISMA model for systematic review was utilized for this search. The research was conducted in the following databases: PubMed, Web of Science, BIREME, and Science Direct. Based on the inclusion criteria, 31 articles were selected and discussed in this review. The studies listed revealed that the main targets of action for Alzheimer’s disease therapy were reduction of reactive oxygen species and amyloid beta‐protein production, while for Parkinson’s disease reduction of the cellular oxidative potential and the activation of mechanisms of neuronal death. Results showed that a variety of flavonoids is being studied and can be promising for the development of new drugs to treat neurodegenerative diseases. Moreover, it was possible to verify that there is a lack of translational research and clinical evidence of these promising compounds.